SubHero Banner

Iwilfin (eflornithine) – New orphan drug approval

December 13, 2023 - The FDA announced the approval of US WorldMeds’ Iwilfin (eflornithine), to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.

Download PDF